^
Association details:
| Biomarker: | NF1 deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | zoledronic acid (Bone resorption factor inhibitor, Osteoclast inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of NF1 leads to rho GTPase activation and sensitivity to multiple agents in breast cancer
Published date:
11/17/2020
Excerpt:
...drugs as single agents and in combination against mouse tumor xenograft models with the human breast cancer cell lines Hs578T (NF1 null)...Treatment with single agent vincristine or zoledronic acid for 19 days resulted in statistically-significant decreases of 37.3% and 38.9%, respectively (p<0.05) in Hs578T tumor xenografts.
Secondary therapy:
vincristine
